Tolmar Expands Operations with New Laboratory at Rosalind Franklin University

Tolmar, Inc., a specialty pharmaceutical company, has officially opened its new Northern Illinois Laboratory at the Innovation and Research Park (IRP) of Rosalind Franklin University in North Chicago, Illinois. This facility aims to enhance Tolmar’s capabilities in developing and commercializing pharmaceutical products, while also enriching the university’s ecosystem of industry innovation.

Founded in 2007, Tolmar is recognized globally for its expertise in long-acting injectable drug delivery systems. The company specializes in creating and producing injectables primarily targeting urology, oncology, and endocrinology. One of Tolmar’s flagship products is utilized in the treatment of advanced prostate cancer and is available in 89 countries worldwide.

The new research facility not only expands Tolmar’s operational capacity but also complements its existing team in Colorado, which includes researchers, engineers, and operations personnel. This strategic move increases Tolmar’s regional presence, adding to its executive offices and sales operations located in Buffalo Grove, Illinois.

Dr. Dave Loffredo, Tolmar’s Vice President of Innovation, expressed enthusiasm about the expansion. “Tolmar is excited to enhance our development capability, now covering both Colorado and Illinois,” he stated. “After an exhaustive search, we found a great home at Rosalind Franklin’s IRP. Tolmar scientists are eager to be a part of this dynamic research environment and hope to grow our presence at IRP.”

Dr. Stace Porter, Senior Vice President of Development Operations at Tolmar, emphasized the advantages of the new laboratory. “At Rosalind Franklin University’s Innovation and Research Park, Tolmar gains world-class research space and the chance to collaborate with leading scientists and advanced research cores,” he noted. “Surrounded by Lake County’s vibrant network of global life science companies, we’re excited to grow and innovate here.”

Collaboration and Innovation at the IRP

The IRP spans 100,000 square feet and hosts six research centers affiliated with Rosalind Franklin University. These include specialized facilities for Cancer Cell Biology, Immunology, and Infection. Dr. Joseph DiMario, Executive Vice President for Research at RFU, welcomed Tolmar to the university’s growing list of corporate partners.

“We look forward to collaborations that can help accelerate new product development,” Dr. DiMario remarked. “The IRP provides an environment that fosters the kind of intellectual biomedical ‘collisions’ that drive meaningful innovation.”

Tolmar’s addition to the IRP underscores a broader commitment to advancing healthcare through collaborative research and development. As the pharmaceutical landscape continues to evolve, partnerships like this one are vital for fostering breakthroughs that can lead to significant improvements in patient care.

About Tolmar and Rosalind Franklin University

Tolmar is a fully integrated specialty pharmaceutical company focused on the development, manufacturing, and commercialization of pharmaceuticals across multiple therapeutic areas, including oncology, urology, and endocrinology. Its product development and manufacturing facilities are located in Northern Colorado, with executive and commercial headquarters in Buffalo Grove, Illinois.

Rosalind Franklin University of Medicine and Science honors the legacy of Dr. Rosalind Franklin, whose groundbreaking work was instrumental in uncovering the structure of DNA. The university is recognized for its research in diverse fields, including neuroscience, inherited disorders, diabetes, and obesity, and encompasses various colleges and schools dedicated to health and medicine.

For further information about Tolmar and its operations, visit their website at www.tolmar.com. More details about Rosalind Franklin University can be found at rosalindfranklin.edu.